Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 1.69
AGN's Cash to Debt is ranked higher than
65% of the 750 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.39 vs. AGN: 1.69 )
AGN' s 10-Year Cash to Debt Range
Min: 0.32   Max: 1.9
Current: 1.69

0.32
1.9
Equity to Asset 0.61
AGN's Equity to Asset is ranked higher than
66% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.60 vs. AGN: 0.61 )
AGN' s 10-Year Equity to Asset Range
Min: 0.41   Max: 0.64
Current: 0.61

0.41
0.64
Interest Coverage 24.12
AGN's Interest Coverage is ranked higher than
60% of the 460 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 88.77 vs. AGN: 24.12 )
AGN' s 10-Year Interest Coverage Range
Min: 3.29   Max: 46.04
Current: 24.12

3.29
46.04
F-Score: 6
Z-Score: 7.46
M-Score: -2.62
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating margin (%) 28.72
AGN's Operating margin (%) is ranked higher than
95% of the 710 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.34 vs. AGN: 28.72 )
AGN' s 10-Year Operating margin (%) Range
Min: -1.34   Max: 28.72
Current: 28.72

-1.34
28.72
Net-margin (%) 15.64
AGN's Net-margin (%) is ranked higher than
88% of the 710 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.48 vs. AGN: 15.64 )
AGN' s 10-Year Net-margin (%) Range
Min: -6.96   Max: 20.39
Current: 15.64

-6.96
20.39
ROE (%) 15.24
AGN's ROE (%) is ranked higher than
91% of the 713 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. AGN: 15.24 )
AGN' s 10-Year ROE (%) Range
Min: -12.96   Max: 33.78
Current: 15.24

-12.96
33.78
ROA (%) 9.32
AGN's ROA (%) is ranked higher than
90% of the 742 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.94 vs. AGN: 9.32 )
AGN' s 10-Year ROA (%) Range
Min: -6.76   Max: 16.71
Current: 9.32

-6.76
16.71
ROC (Joel Greenblatt) (%) 128.77
AGN's ROC (Joel Greenblatt) (%) is ranked higher than
99% of the 732 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.50 vs. AGN: 128.77 )
AGN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -4.9   Max: 128.77
Current: 128.77

-4.9
128.77
Revenue Growth (%) 9.30
AGN's Revenue Growth (%) is ranked higher than
73% of the 552 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. AGN: 9.30 )
AGN' s 10-Year Revenue Growth (%) Range
Min: -3.1   Max: 19.6
Current: 9.3

-3.1
19.6
EBITDA Growth (%) 60.90
AGN's EBITDA Growth (%) is ranked higher than
97% of the 507 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.80 vs. AGN: 60.90 )
AGN' s 10-Year EBITDA Growth (%) Range
Min: -46   Max: 96
Current: 60.9

-46
96
» AGN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

AGN Guru Trades in Q1 2013

Jim Simons 625,700 sh (+179.7%)
Jeremy Grantham 417,731 sh (+60.83%)
Frank Sands 12,774,895 sh (+7.38%)
Pioneer Investments 1,008,068 sh (+5.59%)
Dodge & Cox 3,564 sh (unchged)
Mario Gabelli 137,730 sh (-1.61%)
Ken Fisher 11,098 sh (-28.6%)
Joel Greenblatt 3,608 sh (-81.38%)
Steven Cohen 22,561 sh (-93.39%)
Ray Dalio 8,719 sh (-93.77%)
» More
Q2 2013

AGN Guru Trades in Q2 2013

Paul Tudor Jones 14,400 sh (New)
Ray Dalio 249,341 sh (+2759.74%)
Joel Greenblatt 29,690 sh (+722.89%)
Steven Cohen 66,132 sh (+193.13%)
Jeremy Grantham 860,731 sh (+106.05%)
Jim Simons 1,000,660 sh (+59.93%)
Pioneer Investments 1,220,561 sh (+21.08%)
Dodge & Cox 3,564 sh (unchged)
Mario Gabelli 126,914 sh (-7.85%)
Ken Fisher 9,015 sh (-18.77%)
Frank Sands 9,598,964 sh (-24.86%)
» More
Q3 2013

AGN Guru Trades in Q3 2013

George Soros 75,000 sh (New)
Steven Cohen 615,599 sh (+830.86%)
Joel Greenblatt 63,459 sh (+113.74%)
Jeremy Grantham 903,161 sh (+4.93%)
Mario Gabelli 127,569 sh (+0.52%)
Daniel Loeb 17,500 sh (unchged)
Dodge & Cox 3,564 sh (unchged)
Ray Dalio 226,041 sh (-9.34%)
Ken Fisher 7,237 sh (-19.72%)
Frank Sands 7,422,715 sh (-22.67%)
Paul Tudor Jones 10,700 sh (-25.69%)
Pioneer Investments 855,672 sh (-29.9%)
Jim Simons 386,360 sh (-61.39%)
» More
Q4 2013

AGN Guru Trades in Q4 2013

Andreas Halvorsen 1,438,989 sh (New)
George Soros 90,000 sh (+20%)
Mario Gabelli 127,769 sh (+0.16%)
Dodge & Cox 3,564 sh (unchged)
Jim Simons Sold Out
Frank Sands Sold Out
Pioneer Investments 819,803 sh (-4.19%)
Ken Fisher 6,882 sh (-4.91%)
Jeremy Grantham 727,994 sh (-19.39%)
Joel Greenblatt 34,897 sh (-45.01%)
Paul Tudor Jones 3,600 sh (-66.36%)
Steven Cohen 139,119 sh (-77.4%)
Ray Dalio 40,719 sh (-81.99%)
» More
» Details

Insider Trades

Latest Guru Trades with AGN

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Frank Sands 2013-12-31 Sold Out 1.9%$88.48 - $110.85 $ 133.9240%0
Ray Dalio 2013-12-31 Reduce -81.99%0.14%$88.48 - $110.85 $ 133.9240%40719
Joel Greenblatt 2013-12-31 Reduce -45.01%0.09%$88.48 - $110.85 $ 133.9240%34897
Frank Sands 2013-09-30 Reduce -22.67%0.61%$84.24 - $92.63 $ 133.9249%7422715
Joel Greenblatt 2013-09-30 Add 113.74%0.1%$84.24 - $92.63 $ 133.9249%63459
George Soros 2013-09-30 New Buy0.07%$84.24 - $92.63 $ 133.9249%75000
Frank Sands 2013-06-30 Reduce -24.86%1.27%$81.99 - $116.17 $ 133.9229%9598964
Ray Dalio 2013-06-30 Add 2759.74%0.17%$81.99 - $116.17 $ 133.9229%249341
Joel Greenblatt 2013-06-30 Add 722.89%0.1%$81.99 - $116.17 $ 133.9229%29690
Frank Sands 2013-03-31 Add 7.38%0.35%$91.73 - $111.89 $ 133.9226%12774895
Ray Dalio 2013-03-31 Reduce -93.77%0.12%$91.73 - $111.89 $ 133.9226%8719
Joel Greenblatt 2013-03-31 Reduce -81.38%0.08%$91.73 - $111.89 $ 133.9226%3608
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Allergan, Inc.

Stocks with High Forward Rate of Return, Donald Yacktman’s Measure
Among the criteria Donald Yacktman, conservative value investor who runs the risk-averse Yacktman Asset Management, uses to judge the attractiveness of a stock, he strongly prizes a high “forward rate of return.” Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 41.20
AGN's P/E(ttm) is ranked higher than
55% of the 528 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.60 vs. AGN: 41.20 )
AGN' s 10-Year P/E(ttm) Range
Min: 16.7   Max: 100.02
Current: 41.2

16.7
100.02
P/B 6.20
AGN's P/B is ranked lower than
58% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.84 vs. AGN: 6.20 )
AGN' s 10-Year P/B Range
Min: 2.4   Max: 15.92
Current: 6.2

2.4
15.92
P/S 6.40
AGN's P/S is ranked lower than
67% of the 722 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.99 vs. AGN: 6.40 )
AGN' s 10-Year P/S Range
Min: 2.18   Max: 6.57
Current: 6.4

2.18
6.57
PFCF 26.60
AGN's PFCF is ranked higher than
69% of the 330 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 24.86 vs. AGN: 26.60 )
AGN' s 10-Year PFCF Range
Min: 16.97   Max: 143.81
Current: 26.6

16.97
143.81
EV-to-EBIT 20.40
AGN's EV-to-EBIT is ranked higher than
64% of the 593 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.45 vs. AGN: 20.40 )
AGN' s 10-Year EV-to-EBIT Range
Min: 12.3   Max: 773.3
Current: 20.4

12.3
773.3
PEG 1.10
AGN's PEG is ranked higher than
86% of the 312 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.74 vs. AGN: 1.10 )
AGN' s 10-Year PEG Range
Min: 0.41   Max: 12.32
Current: 1.1

0.41
12.32
Shiller P/E 56.50
AGN's Shiller P/E is ranked lower than
53% of the 362 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.59 vs. AGN: 56.50 )
AGN' s 10-Year Shiller P/E Range
Min: 32.89   Max: 118.3
Current: 56.5

32.89
118.3

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.20
AGN's Dividend Yield is ranked lower than
94% of the 419 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.38 vs. AGN: 0.20 )
AGN' s 10-Year Dividend Yield Range
Min: 0.16   Max: 0.63
Current: 0.2

0.16
0.63
Dividend Payout 0.05
AGN's Dividend Payout is ranked higher than
99% of the 367 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.32 vs. AGN: 0.05 )
AGN' s 10-Year Dividend Payout Range
Min: 0.06   Max: 0.63
Current: 0.05

0.06
0.63
Yield on cost (5-Year) 0.20
AGN's Yield on cost (5-Year) is ranked lower than
92% of the 430 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.42 vs. AGN: 0.20 )
AGN' s 10-Year Yield on cost (5-Year) Range
Min: 0.16   Max: 0.63
Current: 0.2

0.16
0.63
Share Buyback Rate 0.70
AGN's Share Buyback Rate is ranked higher than
89% of the 483 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -2.70 vs. AGN: 0.70 )
AGN' s 10-Year Share Buyback Rate Range
Min: 1.1   Max: -4.8
Current: 0.7

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 116.50
AGN's Price/Net Current Asset Value is ranked lower than
94% of the 310 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.80 vs. AGN: 116.50 )
AGN' s 10-Year Price/Net Current Asset Value Range
Min: 58.67   Max: 438.7
Current: 116.5

58.67
438.7
Price/Tangible Book 16.10
AGN's Price/Tangible Book is ranked lower than
80% of the 629 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.10 vs. AGN: 16.10 )
AGN' s 10-Year Price/Tangible Book Range
Min: 3.34   Max: 118.96
Current: 16.1

3.34
118.96
Price/DCF (Projected) 2.70
AGN's Price/DCF (Projected) is ranked higher than
56% of the 346 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.70 vs. AGN: 2.70 )
AGN' s 10-Year Price/DCF (Projected) Range
Min: 1.3   Max: 6.46
Current: 2.7

1.3
6.46
Price/Median PS Value 1.30
AGN's Price/Median PS Value is ranked higher than
56% of the 665 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.10 vs. AGN: 1.30 )
AGN' s 10-Year Price/Median PS Value Range
Min: 0.36   Max: 2.3
Current: 1.3

0.36
2.3
Price/Peter Lynch Fair Value 1.50
AGN's Price/Peter Lynch Fair Value is ranked higher than
67% of the 145 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.50 vs. AGN: 1.50 )
AGN' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.89   Max: 4.79
Current: 1.5

0.89
4.79
Price/Graham Number 4.70
AGN's Price/Graham Number is ranked lower than
68% of the 461 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.20 vs. AGN: 4.70 )
AGN' s 10-Year Price/Graham Number Range
Min: 1.55   Max: 48.02
Current: 4.7

1.55
48.02
Earnings Yield (Greenblatt) 4.90
AGN's Earnings Yield (Greenblatt) is ranked higher than
69% of the 595 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.80 vs. AGN: 4.90 )
AGN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 8.1
Current: 4.9

0.1
8.1
Forward Rate of Return (Yacktman) 23.61
AGN's Forward Rate of Return (Yacktman) is ranked higher than
91% of the 532 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.45 vs. AGN: 23.61 )
AGN' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -24.6   Max: 51
Current: 23.61

-24.6
51

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, FRX, MRX, ESALF » details
Traded in other countries:AG4.Germany
Allergan, Inc., was founded in 1950 and incorporated in Delaware in 1977. The Company is a multi-specialty health care company focused on developing and commercializing innovative pharmaceuticals, biologics and medical devices that enable people to live life to its greatest potential. The Company discovers, develops and commercializes specialty pharmaceutical, medical device and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, obesity intervention, urological and other specialty markets in more than 100 countries around the world. It is engaged in specialty pharmaceutical, biologic and medical device research and development, with global efforts targeting products and technologies related to eye care, skin care, neuromodulators, medical aesthetics, obesity intervention, urology and neurology. The Company operates its business on the basis of two reportable segments - specialty pharmaceuticals and medical devices. The specialty pharmaceuticals segment produces a range of pharmaceutical products, including: ophthalmic products for chronic dry eye, glaucoma therapy, ocular inflammation, infection, allergy and retinal diseases; Botox for certain therapeutic and aesthetic indications; skin care products for acne, psoriasis, other prescription and over-the-counter skin care products and urologics products. The medical devices segment produces a range of medical devices, including: breast implants for augmentation, revision and reconstructive surgery and tissue expanders; obesity intervention products; and facial aesthetics products. The Company provides global marketing strategy teams to ensure development and execution of a consistent marketing strategy for its products in all geographic regions that share similar distribution channels and customers. The Company faces intense competition from generic drug manufacturers in the United States and internationally. The Company is subject to federal, state, local and foreign environmental laws and regulations.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide